Premium
Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation
Author(s) -
Federico Silvestri,
Anna Ermacora,
Alessandra Sperotto,
Francesca Patriarca,
Francesco Zaja,
D. Doḿınguez Damiani,
Renato Fanin,
Michele Baccarani
Publication year - 2000
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2000.01847.x
Subject(s) - lamivudine , medicine , chemotherapy , hepatitis b , hepatitis b virus , lymphoma , hepatitis , gastroenterology , oncology , immunology , virus
Reactivation of hepatitis B virus in patients receiving chemotherapy for non‐Hodgkin's lymphoma (NHL) may give rise to hepatitis, hepatic failure and death, and prevent further chemotherapy. We report four patients with NHL in whom hepatitis flare‐up was observed after two (three patients) and six (one patient) cycles of chemotherapy. After spontaneous recovery, they were treated with Lamivudine (100 mg/day), which enabled completion of chemotherapy without further hepatitis B reactivation. In one patient, high‐dose chemotherapy and autologous stem cell transplantation was also performed. These data suggest a possible role for Lamivudine in preventing hepatitis B reactivation during chemotherapy administration to chronic carriers of the hepatitis B virus. Moreover, it enabled the completion of both standard and high‐dose chemotherapy in patients with previous hepatitis B reactivation.